March 18, 2020

Information from LabCorp about coronavirus disease 2019 (COVID-19)

MARCH 18, 2020 - 11:

Read more »

March 16, 2020

Labcorp rapidly expanding its COVID-19 testing capacity, expects ability to perform 10,000 tests per day by the end of the week and 20,000 tests per day by the end of March

MARCH 16, 2020 - 8:4

Read more »

December 12, 2019

Serum vedolizumab and corresponding anti-vedolizumab antibody: Analysis of over 6500 patient results using lab developed chemiluminescent immunoassays (ECLIA)

Read more »

Serum vedolizumab and corresponding anti-vedolizumab antibody: Analysis of over 6500 patient results using lab developed chemiluminescent immunoassays (ECLIA)

December 12, 2019

Serum ustekinumab and corresponding anti-ustekinumab antibody: Analysis of over 2000 patient results using lab developed chemiluminescent immunoassays (ECLIA)

Read more »

Serum ustekinumab and corresponding anti-ustekinumab antibody: Analysis of over 2000 patient results using lab developed chemiluminescent immunoassays (ECLIA)